The Interleukin-17 Pathway in Psoriasis and Psoriatic Arthritis: Disease Pathogenesis and Possibilities of Treatment

PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

DOI: 10.1007/s11926-014-0414-y

Cite this article as:
Frleta, M., Siebert, S. & McInnes, I.B. Curr Rheumatol Rep (2014) 16: 414. doi:10.1007/s11926-014-0414-y
Part of the following topical collections:
  1. Topical Collection on Psoriatic Arthritis

Abstract

Psoriasis and psoriatic arthritis (PsA) are pathophysiological enigmas among rheumatic diseases. Substantial clinical advances have been made with new therapy targeting different components of the IL-17 and IL-23 pathways. At the same time, an increase in research on the topic has provided new insights into the potential functional effects of treatments on cell types, pathways, and tissues of interest. Here we review our knowledge of all IL-17 family members, their relationships with the IL-23 pathway, and the outcomes of relevant clinical trials in which different strategies for targeting these molecules have been tested in the treatment of moderate to severe psoriasis and PsA.

Keywords

Psoriatic arthritis Psoriasis Interleukin-17 IL-17 Interleukin-23 IL-23 Biologic agents Pathogenesis Treatment 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Marina Frleta
    • 1
  • Stefan Siebert
    • 1
  • Iain B. McInnes
    • 1
    • 2
  1. 1.University of GlasgowGlasgowUK
  2. 2.Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life SciencesGlasgow Biomedical Research CentreGlasgowUK

Personalised recommendations